At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
Tocilizumabdrug
Likely dose
Tocilizumab 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib, Open-Label, Dose-Ranging Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Administered by Intravenous Infusion to Patients With Giant Cell Arteritis
In Brief
A Phase 1 clinical trial evaluating Tocilizumab for Giant Cell Arteritis. Completed, enrolled 24 participants across 2 sites.
Detailed Summary
This study will evaluate the pharmacokinetics, pharmacodynamics, and safety of two dose levels of tocilizumab (TCZ) administered by intravenous (IV) infusion every 4 weeks (Q4W) to participants with giant cell arteritis (GCA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGiant Cell Arteritis
CountriesSwitzerland
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedApr 2019
Enrollment StartAug 2019
Primary CompletionNov 2020
TodayJul 2026
First PostedApr 23, 2019
Enrollment StartAug 5, 2019
Primary CompletionNov 12, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.2 years ago
Interventions
Tocilizumabdrug
TCZ will be administered by IV infusion at two dose levels Q4W. The maximum dose of TCZ that will be administered is 800 mg. The dose of TCZ infusion will be calculated on the basis of body weight measured prior to each infusion.